1. Basic Information
Product Name: Survodutide Peptide (BI 456906)
Classification: Long-acting synthetic dual-receptor agonist twincretin peptide
Structure: 29-amino-acid acylated peptide with C18 fatty acid modification for prolonged stability
Purity: ≥98%–99% (HPLC tested, research grade)
Appearance: White sterile lyophilized powder
Survodutide is an advanced next-generation synthetic twincretin peptide independently developed for metabolic research. Designed based on the native oxyntomodulin structure, it serves as a potent dual agonist targeting GLP-1R and GCGR receptors. With a unique C18 fatty acid side chain and optimized amino acid modification, it possesses superior molecular stability, longer half-life and stronger receptor affinity. It features excellent biocompatibility, stable in-vivo metabolism, no accumulation and no dependence, supporting efficient and sustained metabolic regulation for long-term research application.
2. Mechanism of Action
Survodutide exerts dual synergistic metabolic regulation by simultaneously activating GLP-1 and Glucagon receptors. The GLP-1 receptor activation suppresses appetite, delays gastric emptying, enhances satiety, and improves glucose-dependent insulin secretion to stabilize glycemic levels and reduce insulin resistance. Differing from single-target peptides, its GCGR agonism further boosts hepatic energy metabolism, accelerates fatty acid oxidation, and increases systemic energy expenditure.
This dual-pathway mechanism achieves complementary metabolic optimization. It effectively inhibits visceral fat accumulation, improves abnormal lipid metabolism, and alleviates chronic metabolic inflammation. It repairs hepatic metabolic dysfunction, reduces liver fat deposition, and comprehensively corrects various sub-health problems caused by metabolic disorders, realizing dual regulation of energy intake and energy consumption.
3. Core Biological Functions
Powerful Fat Reduction & Body Shaping Survodutide significantly accelerates whole-body fatty acid decomposition and energy consumption, efficiently reduces subcutaneous and visceral fat accumulation, and optimizes body fat ratio. It improves overall body composition without causing lean muscle loss, delivering stable and sustainable body metabolism optimization effects.
Stable Glycemic Regulation & Insulin Sensitivity Improvement It regulates fasting and postprandial blood glucose in a glucose-dependent manner, promotes healthy insulin secretion, reduces insulin resistance, and maintains long-term glycemic homeostasis. It effectively prevents metabolic fluctuations without triggering hypoglycemia risks.
Hepatic Metabolism Repair & Lipid Improvement By activating glucagon receptors, it specifically enhances hepatic fat metabolism, reduces liver lipid deposition, repairs abnormal liver metabolic function, and improves sub-health conditions related to lipid metabolic disorders and fatty liver tendency.
Appetite Regulation & Metabolic Balance Optimization It prolongs satiety duration, suppresses excessive food cravings and calorie over-intake, regulates dietary metabolism rhythm, and establishes a balanced energy metabolism cycle to prevent recurring metabolic sub-health problems.
4. Reconstitution and Concentration Specification
10 mg Survodutide lyophilized powder reconstituted with 5 mL BAC water
Final Concentration: 2 mg/mL
Note: Each 1 mL of reconstituted solution contains 2 mg of active Survodutide polypeptide.
5. Safety Profile
Survodutide is a high-purity synthetic modified peptide with mild, stable and highly targeted regulatory effects. It has excellent human biocompatibility, no systemic toxicity, no local irritation, no hormone interference and no drug dependence. After completing metabolic regulation in vivo, it can be completely decomposed and metabolized without tissue accumulation or adverse side effects, suitable for long-term laboratory research use.
6. Storage Instructions
Sealed lyophilized powder should be stored at -20°C, kept sealed, dry and protected from light. Reconstituted solution must be stored at 2–8°C and used within 7 days to maintain optimal biological activity and prevent peptide inactivation.
7. Disclaimer
Survodutide Peptide is a research-grade experimental peptide for laboratory research and technical reference only. It is not a pharmaceutical product and shall not be used for medical diagnosis, treatment or clinical medication purposes.